Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).
about
Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancerIs there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of boneA reproducible approach to high-throughput biological data acquisition and integrationModulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1Cancer stem cells in human gastrointestinal cancers.Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer.A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivationAcyl-coenzyme A binding domain containing 3 (ACBD3; PAP7; GCP60): an emerging signaling molecule.Genome-wide gene expression profile analyses identify CTTN as a potential prognostic marker in esophageal cancer.DNA microarray wet lab simulation brings genomics into the high school curriculum.HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumorsHigh Dickkopf-1 expression is associated with poor prognosis in patients with advanced urothelial carcinoma.Bioinformatics for cancer management in the post-genome era.How will lung cancer be treated in the future?Epidermal growth factor receptor inhibition and non-small cell lung cancer.Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.Functional selectivity of EGF family peptide growth factors: implications for cancer.Somatic pharmacogenomics in cancer.Targeting EGFR resistance networks in head and neck cancer.Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates.Array-based pharmacogenomics of molecular-targeted therapies in oncology.A systematic approach to the development of novel therapeutics for lung cancer using genomic analyses.Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis.Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of responseSNRFCB: sub-network based random forest classifier for predicting chemotherapy benefit on survival for cancer treatment.Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway.Genetics of papillary thyroid cancer initiation: implications for therapyClinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer.Characterization of KIF11 as a novel prognostic biomarker and therapeutic target for oral cancer.Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer.
P2860
Q24294641-1B64E502-02AD-40C6-AC3B-EF7388FD787FQ26798882-41DD092B-6C2D-4CBA-A399-AF6FA0271B02Q26866067-5D1D65FF-D429-467C-9321-AD6BA1B8DED4Q28647460-328B6C63-3E14-4DF7-838D-D15C710C0E6FQ28655621-AECB05D5-7E9A-42EF-83D9-A16957C5A0C5Q33241381-E839EF64-BC39-49E3-A4EA-13140E07CB6CQ33251551-6C5DB5DF-FAEF-4E3E-A217-97EFDA444600Q33618157-A83B82F5-034D-4B06-BFD8-EF6DFA96D1AAQ33731181-8DEBD63D-18C7-4AB0-94DF-E680858DEAB9Q33845082-E67A6426-28F9-4F12-BACD-1DA8B80394E2Q33862407-E6CD7FCE-829B-447D-A11D-0C86D1188E85Q35097632-29035549-4087-4108-80A1-B8CBE941C9CCQ35193323-C64ACFF7-308E-4374-89D7-95C3ABB4B6BBQ36025680-0B5FEDC0-CBC3-451C-8797-0013103BDD05Q36244287-F4954848-A6B0-4E6C-82E0-E2AE3EDE257BQ36427239-25BDC074-EDFC-4DB7-9D37-ADBEBFDC2DD5Q36429550-BCBE06BB-22E3-4D1C-8F77-62D56D32E10DQ36504349-3D8ADC05-E259-4109-A24C-D6AFC7C4312CQ36610132-57C89FFD-9DA9-4EF2-A974-BC0239836CC1Q37004639-26E6C428-BBEC-4D20-BAE1-CD3A3CC5A592Q37149729-0E7D2D6B-0C4B-4B9C-87A0-E04DD56C416CQ37235024-82EB535D-ADF2-4F58-B1E0-4171E0519549Q37405633-515F4026-29EA-4E02-9EEB-A2B198EADFBBQ37755154-C601D63E-7425-45CF-9FC2-2B46B25C6365Q37976288-0E237A51-611D-4B3D-BBAE-AF99EE910BEAQ38105238-E7ECF658-9020-4BF5-8865-E5121937A38CQ38406799-25449941-9C5B-4A04-AAF7-5A1E6669F676Q39308117-B9674683-961B-4B34-83AC-204467D7F8B4Q39340631-50D8CF24-C29E-48CB-993E-3DEB71E7D587Q39799281-A30A0FA3-1BD0-4593-B249-CD7926FD5BF7Q40007032-8EBCDD98-6A1C-436B-A79B-024A914EFDC8Q40147314-9A7CFAA5-62CC-4ADC-A40C-4AFCB97939C6Q41908055-B34BC410-776C-4348-A62A-B94170B55EADQ46351405-9244A518-548B-460A-9E7E-176E664BBF0BQ47426544-6579E6F9-315A-44B3-9255-211CD9BAAE1BQ51047134-5C9B0C39-93A7-41DB-919C-1B0F60AFC286
P2860
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Prediction of sensitivity of a ...... to gefitinib (Iressa, ZD1839).
@en
Prediction of sensitivity of a ...... to gefitinib (Iressa, ZD1839).
@nl
type
label
Prediction of sensitivity of a ...... to gefitinib (Iressa, ZD1839).
@en
Prediction of sensitivity of a ...... to gefitinib (Iressa, ZD1839).
@nl
prefLabel
Prediction of sensitivity of a ...... to gefitinib (Iressa, ZD1839).
@en
Prediction of sensitivity of a ...... to gefitinib (Iressa, ZD1839).
@nl
P2093
P2860
P356
P1476
Prediction of sensitivity of a ...... to gefitinib (Iressa, ZD1839).
@en
P2093
Chiyuki Furukawa
Kazuhiko Nakagawa
Masahiro Fukuoka
Nobuhisa Ishikawa
Nobuoki Kohno
Saburo Sone
Seiji Yano
Soji Kakiuchi
Takashi Tsuruo
Tatsuhiko Tsunoda
P2860
P304
P356
10.1093/HMG/DDH331
P577
2004-10-20T00:00:00Z